Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR1 | P25103 | 1/20 | 0.38 |
| ▸ | BACE1 | P56817 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.31 |
| ▸ | GAA | P10253 | 3/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3974971 | 0.88 | ALDH1A1 (0.38) | ALDH1A1GAAHPGDKDM4EL3MBTL1 | |
| SCHEMBL3978288 | 0.86 | ALDH1A1 (0.34) | ALDH1A1GAAHPGDKDM4EL3MBTL1 | |
| SCHEMBL4248617 | 0.85 | ALDH1A1 (0.33) | ALDH1A1GAAHPGDKDM4EPOLB | |
| SCHEMBL3977528 | 0.83 | GAA (0.35) | ALDH1A1GAAHPGDKDM4EPOLB | |
| SCHEMBL3984992 | 0.82 | KDM4E (0.35) | ALDH1A1GAAHPGDKDM4EPOLB | |
| SCHEMBL3975937 | 0.82 | ALDH1A1 (0.36) | ALDH1A1GAAHPGDKDM4EL3MBTL1 | |
| SCHEMBL3980870 | 0.80 | IKBKB (0.34) | ALDH1A1GAAHPGDKDM4E | |
| SCHEMBL3977604 | 0.80 | ALDH1A1 (0.33) | ALDH1A1GAAHPGDPOLB | |
| SCHEMBL4282780 | 0.80 | GAA (0.32) | ALDH1A1GAAHPGDKDM4E | |
| SCHEMBL3979485 | 0.78 | MAPT (0.41) | ALDH1A1GAAHPGDKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7514452-B2 | 2-furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON PHARMACEUTICAL CO., LTD (JP) | 2009-04-07 | — | — | US | disclosed |
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-04 | — | — | US | disclosed |
| EP-1489077-A1 | 2-FURANCARBOXYLIC ACID HYDRAZIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | DAINIPPON PHARMACEUTICAL CO., LTD. (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050171196-A1 | 2-Furancarboxylic acid hydrazides and pharmaceutical compositions containing the same | GLP1R, GCGR, GPR119 | TACR1 485/4885BACE1 2433/4885ALDH1A1 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.